Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DTC User Fee Program’s Demise Leaves Advertisers Bobbing In Its Wake

Executive Summary

FDA's formal termination of the user fee program for review of direct-to-consumer advertising does not resolve the regulatory uncertainty surrounding the ads. Sponsors are now faced with the prospect of stricter penalties for advertising violations without an expedited means of obtaining immunity from them

You may also be interested in...



DTC Pre-Review Guidance In The Works For Rx TV Ads, FDA’s Abrams Says

Certain drug classes will be required to submit certain types of ads, according to Tom Abrams, director of CDER’s recently elevated Office of Prescription Drug Promotion, but specifics will await the guidance itself.

Industry Missing A Public Health Opening With DTC Ads, FDA’s Hamburg Says

The messages conveyed through pharmaceutical direct-to-consumer advertising, and FDA’s role in regulating such promotions, are ripe for re-examination, Commissioner Margaret Hamburg said July 25.

Industry Missing A Public Health Opening With DTC Ads, FDA’s Hamburg Says

The messages conveyed through pharmaceutical direct-to-consumer advertising, and FDA’s role in regulating such promotions, are ripe for re-examination, Commissioner Margaret Hamburg said July 25.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS049202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel